Brainsway Q2 2025 Earnings Call Transcript

Quartr
Provided by Quartr
August 13, 2025

Key Takeaways

  • Positive Sentiment: We delivered record quarterly revenue of $12.6 million, up 26% year-over-year, and shipped 88 Deep TMS systems—a 35% increase—raising our installed base to 1,522 systems.
  • Positive Sentiment: Multi-year lease agreements now represent 70% of customer engagements, contributing to a $62 million backlog of remaining performance obligations and providing clear revenue visibility.
  • Positive Sentiment: The company raised full-year 2025 guidance to $50 million–$52 million in revenue (22–27% growth) with expected operating profit of 4–5% and adjusted EBITDA of 12–13%.
  • Positive Sentiment: Data for an accelerated Deep TMS protocol reducing the acute phase from four weeks to six days have been submitted to the FDA, with a decision expected in Q4 2025, potentially boosting patient adoption.
  • Neutral Sentiment: As part of a new strategy, we completed a $5 million minority investment in Stella MSO and aim for at least five similar partnerships in 2025 and ten more in 2026 to expand clinic access.
AI Generated. May Contain Errors.
Earnings Conference Call
Brainsway Q2 2025
00:00 / 00:00

There are 6 speakers on the call.

Speaker 3

Good day and welcome to the BrainsWay Second Quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Garth Russell with investor relations from LifeSci Advisors. Please go ahead.

Operator

Thank you all, and welcome to BrainsWay's Second Quarter 2025 earnings conference call. With us today are BrainsWay's Chief Executive Officer, Hadar Levy, and Chief Financial Officer, Ido Marom. The format for today's call will be a discussion of recent trends and business updates from Hadar, followed by a detailed discussion of the financials. We will open up the call for your questions. Earlier today, BrainsWay released financial results for the three months ended June 30, 2025. A copy of this press release is available on the company's investor relations website.

Operator

Before I turn the call over to Hadar, I would like to remind you that this conference call, including both management's prepared remarks and the question-and-answer session, may contain projections or other forward-looking statements regarding, among other topics, BrainsWay's anticipated future operating and financial performance, business plans and prospects, and expectations for its products and pipeline, which are all subject to risks and uncertainties, including shifts in the market conditions resulting from geopolitical, supply chain, and other factors, as well as the use of non-GAAP financial measures. Additional information regarding these and other risk factors is available in the company's earnings release and in its other filings with the SEC, including the risk factors section contained in BrainsWay's Form 20-F. I would like to turn the call over to Hadar.

Speaker 3

Thank you, Garth. Welcome everyone, and thank you for joining us today. We are excited to announce record quarterly revenue of $12.6 million reported for the second quarter of 2025. This represents a 26% increase compared to the same period last year. In addition, we shipped a total of 88 Deep Transcranial Magnetic Stimulation (Deep TMS) systems during the quarter, representing a 35% increase compared to the same period last year. This brings our total install base to 1,522 systems. A key part of our success, which has allowed us to report steady growth and strong gross margin, is our focus on generating recurring revenue streams through multi-year lease agreements. These agreements now make up approximately 70% of our recent customer engagement.

Speaker 3

In addition to signing new agreements, we have had a high rate of customer retention, with many customers deciding to extend and even extend their agreement out several years. Currently, we have a backlog of signed agreements with remaining performance obligations totaling approximately $62 million. This backlog provides us with a clear visibility into the future and a foundation from which to grow. We believe the stability and visibility in our business, driven by the growing share of customer engagement tied to multi-year leasing agreements over the past several quarters, clearly demonstrate our evolution from a pioneer of breakthrough technology into a scalable growth platform. With the wind at our backs, we have been able to further establish our leadership position in the non-invasive neuromodulation space. I am proud of how efficient our team is at executing our business model, which is designed to innovate, repeat, extend, and compound.

Speaker 3

Thus far, under this model, we have focused on three key pillars to drive long-term growth, including further elevating market awareness of Deep TMS and its clinical impact, advancing our R&D roadmap to unlock new and expanded treatment indications, and broadening patient access through global expansion and health system integration. At the core of these three initiatives are our regulatory approvals and clinical data, which continue to set Deep TMS apart, elevating our platform in the market. As a reminder, Deep TMS is the only TMS modality cleared by the FDA and with peer-reviewed published clinical evidence for a broad range of indications, including depression, anxious depression, late-life depression, obsessive-compulsive disorder (OCD), and smoking addiction. Recently, we announced BrainsWay would provide an independent educational grant to fund two new continuing medical education, or CME, courses designed to extend clinician knowledge and confidence in the use of Deep TMS.

Speaker 3

These activities aim to deepen understanding of our robust clinical evidence supporting TMS, clarify distinction between Deep TMS and first-generation figure-of-eight coil TMS, and provide practical guidance for integrating TMS into clinical practice. The courses are led by key opinion leaders in the field of psychiatry and brain stimulation, and we are proud to be able to support this effort. Over the past two years, we have focused on strengthening our engagement with large enterprise customers and building valuable partnerships to drive sales. This approach has benefited us to our customers as they receive higher-end engagement and support from our team. Most recently, we achieved an extensive order of systems with a multi-phase delivery plan through the end of the year by a fast-growing U.S. mental health network in the Western and Southern U.S. As an update on our clinical initiative, we recently submitted data to the U.S.

Speaker 3

FDA from our randomized multicenter U.S. clinical trial, which evaluated an accelerated treatment protocol for the Deep TMS system for major depressive disorder treatment as compared to the current standard of care Deep TMS protocol. As a reminder, the traditional Deep TMS protocol involves a four-week acute treatment phase with one session on each day of treatment. This is now being compared to an accelerated protocol, which involves a significantly shorter acute phase taking place over several treatment days. We believe this accelerated protocol has the potential to improve convenience and thereby make Deep TMS substantially more appealing to prospective patients. We're also continuing to progress with the Israel Ministry of Defense Rehabilitation Department in qualifying patients with post-traumatic stress disorder or PTSD for Deep TMS and will keep you posted on any changes.

Speaker 3

Moving on to our investment initiative, as previously announced, in late 2024, we identified a new opportunity to generate shareholder value by making minority interest investment in mental health providers, as well as other enterprises that we believe are complementary to our business. This strategy allows us to tap into a market we know well, building additional market awareness, R&D roadmap, data analysis capability, and expanding access to Deep TMS while avoiding stepping into an operational role outside of our core focus as a Deep TMS technology company. To support us in this initiative, we engaged a value equity partner, which made a $20 million strategic equity investment in our company. This investment provided us with the capital needed to quickly move ahead with this strategy on a broader and more meaningful scale.

Speaker 3

We are pleased with the rollout of this initiative and recently made an initial investment at the end of the second quarter. Under this agreement, we completed a $5 million financing transaction with Stella MSL, a management services organization servicing more than 20 mental health clinics across the U.S. that have treated over 30,000 patients to date. This is just the first of what we expect to be many investments under this strategy. We are actively engaged with several other mental health clinics and enterprises for similar engagement. We look forward to keeping you updated on this initiative. We believe that these activities are critical as we work to further cement our role in shaping the future of mental health treatments. With that, I will now turn the call over to Ido for his review of our second quarter 2025 financial results. Ido.

Speaker 5

Thank you, Hadar. As Hadar noted, Q2 2025 was another record quarter for BrainsWay, with revenue of $12.6 million, representing a 26% increase compared to $10 million in the same period last year. During the quarter, we placed 88 Deep Transcranial Magnetic Stimulation (Deep TMS) systems, bringing our total install base to 1,522 systems as of June 30, 2025, compared to 1,215 systems a year ago. Gross profit for the quarter was $9.5 million, up $2 million from $7.5 million in the prior year period, while maintaining a strong gross margin of 75% in both periods. This stability continues to reflect the strength of our recurring revenue model and disciplined cost management. Turning to operating expenses, sales and marketing totaled $4.9 million compared to $3.8 million in Q2 2024, an increase of $1.1 million, driven by targeted investment in commercial expansions and marketing programs.

Speaker 5

Research and development expenses were $2.3 million compared to $1.7 million last year, an increase of $0.6 million, primarily from our ongoing clinical trials and development activities. General and administrative expenses were $1.6 million compared to $1.4 million in the prior year period, an increase of $0.2 million, mainly due to additional legal fees and due diligence costs related to the Stella MSL investment and other initiatives, as reflected in our adjusted EBITDA reconciliation table, including in our press release issued earlier today. Operating profit was approximately $600,000, in line with the same period last year. Adjusted EBITDA increased to $1.5 million from $1.3 million in a prior year period. Net profit for the quarter was $2 million compared to $0.6 million in the same period of 2024.

Speaker 5

From a balance sheet perspective, we ended the quarter with $78.3 million in cash, cash equivalents, restricted cash, and short-term deposits, up $8.7 million from the end of 2024 and up $30.2 million from the same point last year. This increase was driven primarily by very strong collections during the quarter and was offset by our deployment of $5 million for the minority equity investment in Stella MSL as part of our strategic initiatives. Our strong cash position also reflects the equity financing completed in Q4 2024, which provided the resources to fund these growth investments while maintaining significant liquidity. In addition, deferred revenue also increased meaningfully, largely due to advanced collections from a significant multi-year agreement with a growing mental health network. As a result, remaining performance obligations grew to $62 million, a 25% year-over-year increase, providing strong visibility into future revenues.

Speaker 5

Cash flow from operations in the quarter was positive, further reinforcing the strengths of our recurring model and high collection efficiency. Our capital structures remain debt-free, giving us significant flexibility to pursue strategic growth initiatives, including the investment program Hadar outlined earlier. Based on our strong first half results, LC backlog, and continued momentum in both U.S. and international markets, we are raising our full-year 2025 revenue guidance to a range of $50 to $52 million, representing 22% to 27% growth over 2024 revenue. We now expect operating profit in the range of 4% to 5% of revenue and adjusted EBITDA in the range of 12% to 13% for the year. This concludes my remarks, and I will now turn the call back to the operator to please open the call for questions. Operator?

Speaker 3

Certainly, thank you. We will now begin the question-and-answer session. To ask a question, you may press star, then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. At this time, we will pause momentarily to assemble our roster. Our first question comes from Jeffrey Scott Cohen with Ladenburg Thalmann & Co. Inc. Please go ahead.

Speaker 1

Good morning, Hadar and Ido. Thanks for taking our questions. I guess firstly, Hadar, could you talk about the accelerated protocol in the sense of if or when that comes to market as far as treatment days and potential pricing and payer flow, at least domestically, please?

Speaker 3

Yeah, good morning, Jeff. As I said as part of my earlier call, we already submitted the data to the FDA, and we also published the initial results from the study that looks very, very positive. In terms of timing, we're expecting to receive an answer from the FDA in the fourth quarter of this year with the hope to potentially even get a clearance before the end of the year. In terms of the commercialization part of this, we believe that's going to be a game changer. We believe that you now may shorten the daily visit at the clinic for only a few days. We're talking about six days instead of four weeks acute phase plus additional two weeks of maintenance treatment, overall six weeks. You compare six weeks to six days.

Speaker 3

That's really going to make it much easier and much more comfortable for patients to come and do this meaningful and important treatment at the clinic. In terms of reimbursement, the current reimbursement is currently allowing up to two treatments per day. We are actively working on that to try and improve it to match our new protocol for the accelerated in order to continue and expand this new indication in 2026.

Speaker 1

Okay, got it. That's helpful. Could you talk about the FDA's and the size of the commercial organization and talk about the size over the past year and how they may look into the future?

Speaker 3

The FDA, are you calling to the specifics?

Speaker 1

The full-time employees in the sales organization.

Speaker 3

Okay. The current sales team is around 16 direct sales folks spread out in the US. However, we do have an additional 10 FC practice development folks that are responsible for the utilization and supporting all our current customers and new customers with training and installation. Overall, we're speaking about 26 people that are supporting the sales activity.

Speaker 1

Got it. Lastly, I didn't hear any commentary regarding TMS 360 and the pilot study. Any updates there? Thank you.

Speaker 3

Yeah, the TMS 360 system, our plan is to launch the TMS 360 system with the alcohol use disorder trial, which we plan to launch in the third quarter, let's say by the end of September. That will be the first use of the TMS 360 system. However, we also do some feasibility studies with this system around cognitive behavior and Parkinson's in some qualitative centers in the U.S. and maybe also in Europe before the end of the year. I believe this next-gen TMS 360 system will be used, one, for feasibility studies on some neurology indications, but also it's going to be the main system for the alcohol use disorder that we're planning to launch during this year.

Speaker 1

Perfect. Thanks for taking our questions. Nice quarter.

Speaker 3

Thank you, Jeff. Our next question comes from the line of Carl Edward Byrnes with Northland Capital Markets. Please go ahead.

Speaker 4

Congratulations on your results. You know, with respect to the backlog, I would imagine that the supermajority of that is from enterprise customers. If you could elaborate, that would be great. Also, what was the OCD placements during the quarter? If you can reference that number as well, thanks.

Speaker 3

Yeah, as you mentioned, we continue to focus on the multi-year lease agreements that most of them are coming from enterprise accounts. We'll continue to focus on enterprise accounts that are generating a substantial lease agreement for us, and that helps us to continue and increase our backlog, the remaining performance obligation, and most important, the visibility for the next, at least for the next year or so. I'm expecting this momentum to continue and stay very positive. In terms of the OCD, we ship 30 OCD systems in the second quarter.

Speaker 4

Great, thank you.

Speaker 3

Thank you, Carl. Our next question comes from Raghuram Selvaraju from H.C. Wainwright. Please go ahead.

Speaker 2

Good morning. This is Dan Onfarrand. Thanks for taking our questions and congratulations on the earnings beat. We were curious, about how many more of these strategic financing arrangements are you planning this year? If you have a planned number, what's likely to be the capital outlay for investment? Do you have a max cap for investment, or is it going to be a flat rate moving forward?

Speaker 3

Thank you for this question. That is going to be a very strategic initiative for the company. We believe that there is a very high interest for this collaboration with growing and profitable mental health networks. The goal, my personal goal and the company goal, is to sign at least five contracts before the end of the year, similar to what we announced with Stella MSL. For 2026, the goal is to have 10 contracts. Overall, we're speaking about a potential 15 contracts by the end of 2026. The size of this minority investment could range between $2 million up to $5 million, depending on the size of the mental health network and the profitability and their plan to expand.

Speaker 3

Overall, as I said, we are actively speaking with a few players today in the market, and my hope is to hit the target that we set to ourselves to sign five new agreements before the end of the year.

Speaker 2

Awesome. That's really exciting. Could you also just qualitatively talk about how the Stella financing arrangement's been working out so far?

Speaker 3

Oh, that's from our perspective, that's a great example of collaboration. When we launched this collaboration with Stella MSL, we do what we are used to do. Besides bringing the best technology into their centers, it's putting lots of emphasis on educating the centers, training the centers on what is working and what is broken in the process, and how they can yield more patients into this treatment modality. We're seeing some dramatic increase in the utilization. I think we are seeing over a 50% increase in the utilization for TMS patients at Stella MSL Clinic. That's fantastic. I really believe in the experience and the playbook that my team already administered with Stella, and that's our plan to do the same thing with all the future collaboration with other mental health networks.

Speaker 2

That sounds awesome. Thank you so much.

Speaker 3

Thank you. Thank you. Again, if you have a question, please press star, then one. We have no further questions at this time. I would like to turn the conference back over to Hadar Levy for any closing remarks. I would like to thank all the investors, analysts, and other participants for their interest in BrainsWay. With that, please enjoy the rest of your day. Thank you. Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Powered by Quartr